Peering into the mystery of disease
An interview with German researcher Bernard Muschlein, whose work with a new microscope challenges the long-held assumptions on the nature of disease.
"Why should the public be interested in this work?" I asked the German gentleman somewhat naÔvely.
Without pause, he tossed a question back: "Do you think it was important to develop the electron microscope?"
The response turned out to be no exaggeration. Bernard Muschlein, the German gentleman in question, heads a research team which uses a powerful new microscope, the Ergonom 400, to study illnesses such as cancer, AIDS and Legionnaire's Disease. The group's findings are challenging long-held assumptions on the nature of disease itself.
Until now, light-source microscopes could reach magnifications of about 2,000times allowing limited live observation of bacteria, but not of smaller, virus-sized micro-organisms. Electron microscopes can reach magnifications of up to 400,000 times but because they work with x-rays and an evaporated vacuum, cannot be used to view living cultures. The Ergonom 400, a ëlight-source-like' microscope with magnification capability of 25,000 times allows observers to view, for long periods, the development cycle of living micro-organisms as small as viruses.
Such a breakthrough in technology was achieved over a 30-year period by the microscope's inventor, a pioneering German scientist named Kurt Olbrich. He disregarded industry experts who told him that his goal of inventing a new super-microscope was "impossible. There's a physical limit which will not allow it."
Olbrich's invention does seem to overcome known laws of physics, and has baffled some in the optical industry who say it is theoretically impossible for his microscope to work. Yet the proof is in the pudding. After looking into the Ergonom 400, Kurt Zanker, Head of the Institute of Immunology at Witten/Herdecke University, told a reporter for Capital magazine: "It is fantastic. I have never seen such things before." A group of leading scientists in England have called the microscope a major development in the field. Videos taken from the Ergonom 400, in their first showing in the US, were a highlight of a World Research Foundation conference, "New Directions for Medicine," held last October.
Speaking for the facts
Bernard Muschlein, who brought the videos to the US, and was a featured speaker at the conference, is an engineer by training, a health practitioner by profession, and a long-time cancer researcher by passion. In 1987, he suggested to Olbrich that the Ergonom 400, until then used for industrial purposes, should be tried in biological and medical applications as well. Muschlein became the head of a research team doing just that.
"In the beginning, facts do not speak for themselves," Muschlein says in one of the videos. "One has to speak for them until they become the common knowledge of humanity."
The "facts" referred to by Muschlein run "contrary to orthodox medicine, and completely contrary to orthodox research." But not contrary to some unorthodox, or at least largely unknown, research conducted over the past 100 years. In the late 19th century, Antoine Bechamp, a French biochemist and toxicologist, discovered tiny, moving bodies in everything from human beings, animals, and plants, to soil, swamps, air, and water. He called these microscopic forms ëmicrozymas', and believed they were one of the fundamental building blocks of life. Bechamp found that when a life-threathening trauma occurred in an organism, the microzymas could change form and begin destroying the body of their host. Similarly, these microbes could ëdevolve' back into their previous, benign state.
Bechamp concluded that certain conditions in an organism evoked the appearance of specific micro-organisms, and that such micro-organisms were, therefore, a symptom rather than a final cause of disease. Changes which took place within the body led to disease states, he said.
Bechamp's theory of pleomorphism (the occurrence of more than one distinct form of an organism in a single life cycle) contradicted the ëgerm' theory espoused by his more famous contemporary and rival, Louis Pasteur, who determined that germs from outside the body caused disease. Pasteur's theory has held sway in Western medicine for over a century.
But Bechamp was only the first in a long line of researchers who have found evidence of pleomorphism. Gunther Enderlein, in the first third of the 20th century, discovered form-changing micro-organisms which he called ëendobionts'. Von Brahmer later called them ëSiphonosospora polymorpha'. The contemporary Canadian biologist, Gaston Naessens, has viewed and studied the life cycle of such bodies, which he calls ësomatids'*. Over the years, others, including the extraordinary microscope inventor and scientist, Royal Rife**, have also provided evidence of pleomorphism.
Muschlein's work with the Ergonom 400 follows in this tradition. "Von Brahmer and others found a special microbe in the human blood," Muschlein says. "This microbe is present in all human beings. In its early stages of development, it is symbiotic, living friendly within the body, in harmony with the immune system. When a person becomes weakened, by surgery, infection, vaccination, stress, and so on, the microbe changes its cyclogenia (cycle of development). It becomes larger, aggressive, pathogenic, parasitic. These larger forms are found in the blood of people threatened by, or suffering from, cancer. With the Ergonom 400 one can observe at what stage this microbe exists."
By examining the stage of development of this micro-organism in the blood, Muschlein says, one can determine the state of health, or conversely, the level of pre-cancerous or cancerous conditions in the body. One substance that tends to change this micro-organism into larger, more aggressive forms is that old nemesis, sugar. "That means a cancer patient cannot eat refined sugar," Muschlein says. Beyond that, anyone who is sick who wants to heal should also not eat sugar, he contends.
Which foods tend to strengthen the immune system? "Salads," he says. "But for that observation, you don't need the Ergonom 400."
The microscope does have potential applications in such areas as the testing of medical treatments. "For example, if you find 13 or 15 viruses in a blood specimen, and you treat the patient and repeat the test three months later, and find in the same field only three viruses, that's a good control for the effectiveness of your treatment." This new technology, Muschlein says, could make animal testing unnecessary, as the reaction of substances on living cells can now be viewed for long periods under a microscope, rather than in the bodies of laboratory animals.
The Ergonom 400 can be used as a tool for AIDS diagnosis and in the testing of substances to combat AIDS as well. The microscope has been able, for the first time, to discern three distinct stages of the AIDS virus in living tissue. Long before a person tests positive on the AIDS antibody test, Muschlein can see the presence of ëred crimson particles' in the blood, denoting an AIDS infection.
Muschlein has found that the AIDS virus can actually ëtransform' full spectrum white light into red. Healthy red blood cells, he says, transform white light into yellow. Such findings confirm the research that Royal Rife conducted decades ago. Rife discovered that when he used certain frequencies of light to illuminate a specimen under his microscope (frequencies which resonated with the specimen's own unique chemical structure), the micro-organism emitted its own light of a characteristic color. He called this property ëoptical resonance'. Rife also found that micro-organisms could be destroyed by using specific frequencies. He used this discovery to kill cancerous tumors in laboratory animals, and later in human beings. Muschlein says that his preliminary findings confirming Rife's optical resonance work "could open a door into a great field of research."
At present, a total of five Ergonom 400 microscopes are in use by researchers in Germany, England and Japan. Microscope research and development thus far has been funded privately by Muschlein and others. He says over DM2 million have been spent out of pocket. Meanwhile, inventor Kurt Olbrich is working toward a breakthrough which would enable an increase in the Ergonom's magnification of up to two or three times. But for that, Muschlein says, and to further his own research, "we need more money."
As my interview with Muschlein ended, I found myself answering the question I had originally posed to him on the significance of his work: "The implications of this information could completely change the world of medicine," I said.
"There's the rub," he replied.
* For more information on Naessens' work, and his trials with medical and legal authorities, see Christopher Bird's book The Persecution and Trial of Gaston Naessens, published by H.J.Kramer, Inc.
** For more information on the work of Royal Rife, read The Cancer Cure That Worked – Fifty Years of Suppression, by Barry Lynes, published in Canada by Marcus Books.
From theJuly 1991 issue of Share International